Tracers / [11C]evobrutinib

[11C]evobrutinib

Also written as [11C]Evobrutinib; [C-11]Evobrutinib
Radionuclide
C-11 t½ 20.36 min
Modality
PET
Production route
—
Stage
—
Syntheses indexed
3

What it is

Compound class
—
Target / mechanism
Bruton's tyrosine kinase inhibitor PMID 39831838
Clinical application
—
Theranostic pair
—

Regulatory status

FDA
—
EMA (centralised)
—
Other approvals
—
Brand names
—

Clinical use

Typical injected activity
—
Uptake time
—

Reported in the literature. Not a dosing recommendation.

Published syntheses

ModuleCassettePurificationYield %RCP %Precursor / supplierSource
TRACERlab FX (model not stated)
GE HealthCare
—HPLC———37513867
2023 Pharmaceuticals (Basel)
a modified GE TracerLabTM synthesis platform — three clinically relevant BTK inhibitors, [11C]ibrutinib, [11C]tolebrutinib, and [11C]evobrutinib, were synthesized at good RCYs
TracerMaker
Scansys Laboratorieteknik
—HPLC4
no
——39831838
2025 ChemistryOpen
was delivered to a TracerMaker synthesis platform (Scansys Laboratorieteknik, Denmark) — [11C]evobrutinib in RCY of 4 % an Am of 25.3 GBq/μmol
———5.5 ± 1.5%99%—37691152
2024 J Labelled Comp Radiopharm

Need this precursor?We can point you to suppliers for [11C]evobrutinib, or handle the enquiry for you.

Get in touch

Quality control Preliminary — inferred from compound class

Ph. Eur. monograph
—
USP monograph
—
AppearancepHRCP HPLCRCP TLCHPLC UVRadionuclidic (HPGe)Half-lifeActivityEndotoxins (LAL)SterilityFilter integrity
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); organic-phase radiosynthesis assumed from isotope/compound class, no synthesis data confirming it -> GC residual solvents (preliminary)

Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived

Setting up quality control?We can help you scope the equipment needed to release [11C]evobrutinib.

Get in touch

Notes

Added from reverse module search (stage 6); 2 article(s) with C-11.